Browse communities
Browse communities
Presenting a webinar?

3D Cell Culture Without the Fancy Glasses

Mary Strother, Ph.D.
Cell culture is the traditional tool for investigating complex scientific questions related to cell behavior. Growing cells in an environment that more closely resembles the in vivo growth conditions is becoming more commonly accepted as critical to impacting cell behavior.

This webinar will explore many of the cell growth conditions currently in use to achieve 3D cell culture. Some topics covered include: Cell/cell interaction in sphere vs. monolayer; multi-well spheroid culture; transwell to tease out signaling effects; 2D surface effects on cells - micro patterned surfaces.
Jun 23 2011
58 mins
3D Cell Culture Without the Fancy Glasses
More from this community:

Health IT

  • Live and recorded (981)
  • Upcoming (22)
  • Date
  • Rating
  • Views
  • If your organization is reliant on a rapidly aging version of SQL Server, you need to join SQL Server experts Michael McCracken from HOSTING and Rodney Landrum, a Microsoft SQL Server MVP, from Ntirety for this in-depth discussion of the hows, whys and whats of upgrading from Microsoft SQL Server 200X to SQL Server 2014. The interactive webinar will cover:
    •The benefits of upgrading
    •Considerations to understand
    •How to smooth the transition
    •Q & A
  • More than 100,000 information security professionals have invested time, effort and resources to achieve what has long been considered the Gold Standard security certification – The CISSP. Now that the security industry is growing and career trends are shaping the current job market, there is a bigger need to understand where the CISSP fits and what value it brings to any professional undertaking the path to become certified.

    During this panel session you'll hear different perspectives, including that of the hiring manager, recruiter and credential holders themselves around the following questions:

    - How is the CISSP viewed in the market place?
    - Which career paths are worth exploring with a CISSP?
    - What skillset does a CISSP have?
    - Is the CISSP a differentiator for a candidate?
    - How does the CISSP help the professional perform his job?
  • Host-based IDS systems, or HIDS, work by monitoring activity that is occurring internally on a host. HIDS look for unusual or nefarious activity by examining logs created by the operating system, looking for changes made to key system files, tracking installed software, and sometimes examining the network connections a host makes. AlienVault USM features a complete integration of OSSEC, one of the most popular and effective open source HIDS tools.

    In this live webinar, we'll show you how USM helps you get more out of OSSEC with:
    Remote agent deployment, configuration and management
    Behavioral monitoring of OSSEC clients
    Logging and reporting for PCI compliance
    Data correlation with IP reputation data, vulnerability scans and more
    We'll finish up by showing a demo of how OSSEC alert correlation can be used to detect brute force attacks with USM
  • Regardless of the colour of the next UK government that emerges as a result of the May election, the £30-£50bn NHS budget chasm is the abyss that all the parties fear in respect of its thereat to quality health service delivery and re-election.

    With political backs to the abyss, no hostages will be taken. It is not unrealistic to expect a well co-ordinated and concerted offence by politicians and patient organisations alike on industry pricing of innovative speciality and rare diseases medicines:

    With this scenario in mind pharmaphorum is once again working with IMS Health to bring you expert insight into what this means for the UK health system and more specifically market access for specialist treatments in the post-election environment.

    Angela McFarlane, Senior principal IMS Health Local Market Access, Anthony Grosso, Principal Pharmacist at the National Hospital for Neurology and Neurosurgery and Sheela Upadhyaya, previously a NHS Senior Manager with over 17 years of experience in the delivery of services and in commissioning of highly specialised services for rare and ultra rare conditions, combine with pharmaphorum's Paul Tunnah to deliver an accurate analysis and frontline insight as to the already complex roadmap for access is about to change again.

    This one hour event will include analysis of informed predictions which include:

    The NICE HTA criteria will get tougher post end to end review (IMMTreV)
    NICE and the NHS England will join forces to streamline access pre/post NICE
    Risk at local level will be shifted to Providers under the new marginal tariff arrangements; which could indeed see a close to the CDF as the PbR excluded drugs list becomes a thing of a glorious past
    Provider baselines will take the strain of innovation - the tough decisions will be softened by a drive to really accelerate uptake of NICE approved medicines

    How can industry prepare for these changes in what is already a tough and complex environment?
  • Join Ntirety, a division of HOSTING and the leading data services organization in the country, in this discussion of the impact that database administration can have on individuals, organizations and — most importantly — bottom line revenue. This interactive webinar will cover:
    •DBA Burnout and Retention
    •The DBA’s Role in Major Platform Shifts and Regulatory Compliance
    •The Accidental DBA Due to Staff and Skills Shortages
    •The “Half a DBA” Problem -- When You Don’t Need a Full-time DBA
    •The IT Budget Crunch
    •Q & A
  • It's been said that defensive driving is about "driving for the other cars on the road." The same can be said for setting your organization's security strategy and "to think like your enemy". It's a sound practice which focuses on infosecurity practitioners putting themselves in the shoes of their attackers and anticipating where the next threat may be coming from. Using advanced analytics to compile simplified reporting can help to streamline your these efforts, enabling you to more clearly see the threats the attackers may be using and helping you to react faster. Join (ISC)2and NopSec on April 9, 2015 at 1:00PM for a discussion on vulnerability and threat analytics to better secure an organization.
  • Accurate, complete, secure — these are the hallmarks of enterprise data at world-class organizations. In healthcare, the importance of these metrics carries even more importance. That’s why CHRISTUS Health takes a systematic approach to managing its information assets. Operating in more than 60 U.S. cities and half a dozen states in Central and South America, CHRISTUS understands the challenges of building information systems that respect privacy, while enabling the kind of analysis that leads to better patient outcomes.

    During this Health Data Management webcast, learn how CHRISTUS Health assembled a comprehensive data strategy for delivering an advanced analytics infrastructure. You’ll hear how a combination of Data Management tools and Data Governance process addressed core challenges of working with multiple systems across the spectrum of healthcare domains. An in-depth Q&A session will let attendees learn about the best practices that enable operational and clinical efficiencies through this next-generation analytical solution.
  • Osterman Research and (ISC)2 recently conducted a survey of individuals in mid-sized and large organizations on how they choose off-the-shelf applications, how they develop custom applications, and how they select third-party application developers. Join (ISC)², Michael Osterman and a panel of experts for a discussion about the findings from the survey and the state of software development quality on Tuesday, April 7th at 1:00pm Eastern. Attendees will also have the opportunity to download the entire survey report.
  • Hyper-converged storage is turning out to be the buzz phrase of the storage industry in 2015, one with as many confusing and contradictory definitions as there are vendors. In theory, the combining of server and storage tiers into a single entity should deliver better application performance and lower infrastructure costs. In practice, your mileage will vary.

    Join us for this webinar where industry expert Jon Toigo – chairman and co-founder of the Data Management Institute – will help to identify key criteria for making the right infrastructure decision for your business. Mr. Toigo will offer his key criteria in selecting a hyper-converged infrastructure model and he will survey the offerings of leading vendors to identify the “gotchas,” trade-offs and lock-ins of each option so you find the best fit for your company.
  • How do ischemia and fixation impact the quality of your assay results and information transfer? Garbage in! Garbage out! Join Geoffrey Baird MD, PhD and David Chafin, PhD at 9 AM Mountain Time, March 31, 2015, who will discuss the impact of ischemia and fixation on assay results, information transfer and some novel approaches to address these important factors. Dr. Baird is an Assistant Professor of Laboratory Medicine and an Adjunct Assistant Professor of Pathology at the University of Washington. Dr. Chafin is a Principle Scientist, Technology and Applied Research at Ventana Medical Systems Inc.
  • Channel
  • Channel profile
  • An Introduction To Cell Culture Apr 30 2015 4:00 pm UTC 60 mins
    Mark Rothenberg, Ph.D.
    This webinar will introduce the history, theory, basic techniques, and potential pit-falls of mammalian cell culture. It is designed for students and new lab technicians, as well as bench scientists interested in updating their techniques or knowledge in the field.

    Topics to be discussed include:
    • History and practical theories of cell culture and its impact on today’s science
    • The requirements needed to set up a cell culture laboratory
    • Challenges when performing mammalian cell culture and how to overcome them

    About our Presenter:
    Dr. Mark Rothenberg graduated from Emory University with his Ph.D. in Cell and Developmental Biology. Over the past 25 years, Mark has held positions in both academia and industry where he has developed an expertise in the areas of assay development and cell culture. He currently holds the position of Manager Scientific Training and Education with Corning Life Sciences.
  • Tips and Techniques for Serum-free Expansion of hMSCs Recorded: Mar 26 2015 53 mins
    Brian Posey
    There is a great interest in application of human mesenchymal stem cells (hMSCs) in cell therapy and tissue engineering due to their self-renewal, multi-lineage differentiation, immunomodulation, and trophic potential. One of the challenges faced in the clinical application of hMSCs is the need for efficient expansion of these cells in vitro without altering their capacity. Serum-free mammalian cell culture media, in particular, require optimization of the expansion protocols. Even subtle changes in routine handling can have a significant impact on the cells’ potential.

    This seminar will cover the variables that can influence the desired regenerative and differentiation properties including medium selection, vessel surface treatment, impact of the cell source, and seeding density. We will also discuss how users can select the correct conditions for optimized growth and functionality.

    Speaker Biography:
    Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has lead numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
  • A Novel “Thaw and Go” Cell-based Model to Study SLC Transporters Recorded: Feb 24 2015 59 mins
    Na Li, Ph.D.
    As a key determinant of drug pharmacokinetics, transporter mediated drug-drug interaction has garnered significant attention from the pharmaceutical industry and regulatory authorities. Corning offers a comprehensive list of tools to support drug transporter studies and recently introduced Corning® TransportoCells™ products to support in vitro assessment of drug interaction with SLC transporters. This new model provides a convenient “thaw and go” cell-based model with robust activity and consistent performance. In this webinar, we will provide an overview of Corning TransportoCells products along with applications for in vitro-to-in vivo correlation. Validation data will also be presented for the newly available TransportoCells products, including OATP1A2, OATP2B1, PEPT1, PEPT2, and NTCP.

    Presenter Biography:
    Dr. Na Li received her B.S degree in Biology from Fudan University, Shanghai, China, and her Ph.D. in Pharmacology from Dartmouth Medical School, Hanover, NH. Her major research focus is on drug transporters, including interspecies differences in hepatobiliary transporters, transporter quantification, and in vitro-to-in vivo extrapolation of drug pharmacokinetics. At Corning, Dr. Li contributes her expertise in in vitro drug transporter technology and its application in drug ADME.
  • 3D Tissue Models for Analyzing Dermatologic and Respiratory Systems Recorded: Jan 28 2015 51 mins
    Yukari Tokuyama, Ph.D.
    Join us on January 28th for a special Corning-sponsored webinar presented by ATCC®.

    The significance of 3D tissue modeling opens up new possibilities for the study of complex physiological processes in vitro. Advances in cell isolation, media development, substrates, and growth surfaces are leading to culture environments that provide better biological and functional properties than traditional 2D cell culture. These models may provide a more predictive analysis and result in a more streamlined process of drug discovery and development. In this webinar, we will discuss recent developments in 3D modeling using ATCC primary and hTERT immortalized cells with specialized Corning® permeable support culture systems in dermatologic and respiratory studies.

    Presenter Biography:
    Dr. Yukari Tokuyama is a Field Application Scientist at ATCC. Prior to this role, she led the Stem Cell Product Development group and focused on products for human induced pluripotent stem cells and lineage specific differentiation. She earned her Ph.D. in Cell and Molecular Biology from the College of Medicine at the University of Cincinnati, where she studied the mechanism of genomic instability in cancer. She completed her post-doctoral training at the Oregon Health & Science University, Oregon National Primate Research Center, with a research focus on human and non-human primate stem cell biology.
  • Factors to Consider When Choosing Cell-based Assays for Use with 3D Cultures Recorded: Dec 16 2014 60 mins
    Terry Riss, Ph.D.
    Join us for a special Corning sponsored webinar presented by Promega Corporation.

    Cells cultured in 3D model systems often acquire relatively large in vivo-like structures compared to the thickness of a 2D monolayer of cells grown on standard plastic plates. Multicellular 3D culture systems containing more than one cell type and exhibiting formation of a complex extracellular matrix represent a more physiologically relevant environment, yet provide a challenge for assay chemistries originally designed for measuring events from monolayers of cells. There is an unmet need for guidelines for design and verification of convenient and effective assays useful for larger 3D microtissues. Critical factors to consider for each model system and cell type include effective penetration of detection reagents and/or complete lysis of microtissue structures using combinations of detergent and physical disruption. We will present the approach used to verify performance of a bioluminescent ATP detection assay for measuring cell viability, a caspase assay for detecting apoptosis, and cell stress reporter assays to detect mechanisms leading to cytotoxicity. Recommendations for factors to consider when verifying performance of cell health assays on 3D culture models will be presented.

    Speaker Bio:

    Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and has since held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also led efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Senior Product Specialist, Cell Health involved in outreach educational training activities including validating assay systems applied to 3D cell culture models.
  • Tips and Techniques for Culturing and Scaling-Up Primary Cells Recorded: Nov 19 2014 59 mins
    Mark Rothenberg, Ph.D.
    Primary cells can more closely mimic an in vivo-like state and generate more physiologically relevant data than immortalized cells. But unlike immortalized cells, primary cells have complex nutritional needs and require optimized growth conditions. In this webinar, you will learn:
    •Proven techniques for isolating primary cells from tissues
    •The importance of choosing the correct dissociation method
    •Troubleshooting techniques for culturing healthier primary cells.
    •Other topics to be discussed include:
    -Choosing the optimal cell culture surface
    -Selecting the optimal cell culture media 
    -Choosing the correct vessel for scaling-up
  • In Vitro Models For Studying Angiogenesis Recorded: Oct 30 2014 58 mins
    Paula M. Flaherty
    Angiogenesis is the process by which a new blood supply is established from pre-existing blood vessels. It is initiated by degradation of vessel basement membrane, endothelial cell proliferation, invasion, and directional migration towards chemoattractants, tube formation, and finally the establishment of a new vasculature.

    We will discuss a portfolio of Corning products designed to investigate specific stages of angiogenesis through standardized and quantitative in vitro cell-based assays.

    •HUVEC-2 Endothelial Cells—Widely studied endothelial cells that have been pre-screened for responsiveness to VEGF, a prototypic stimulator of angiogenesis
    •ECMs and Chemoattractants—ECMs and key pro-angiogenic chemoattractants for optimal EC propagation, attachment, differentiation, and other key functions
    •Endothelial Cell Invasion and Migration Assays—An enabling platform technology consisting of Corning® FluoroBlok™ microporous permeable supports coated with our unique extracellular matrix proteins for quantitation of endothelial cell migration and invasion
    •Endothelia Cell Tube Formation Assay—A rapid assay system allowing direct screening of angiogenic compounds for their effects on endothelial cell tube formation


    Paula Flaherty is a Technology Manager at Corning Life Sciences. Her team develops strategy and products focused on the modulation of in vitro cell behavior using extracellular matrix, media, vessel design, and growth factors. Prior to joining Corning Life Sciences, Paula studied retinal degeneration at the Berman-Gund Laboratory, Harvard Medical School in Boston, MA. She received her bachelor’s degree in Microbiology from the State University of New York and is an In Vitro Cell Biology Fellow, W. Alton Jones Cell Science Center in Lake Placid, NY.
  • Tips and Tricks to Help Develop and Run Microplate-based Assays Recorded: Sep 25 2014 59 mins
    Mark Rothenberg, Ph.D.
    Are you relying on biochemical and cell based in vitro assays in your research? In this webinar, Dr. Mark Rothenberg will share “insider” tips and tricks for enhancing your biochemical and cell-based assay performance.
    Critical parameters for achieving success with these assays include understanding the assay dynamics, the instrumentation involved in reading the assay, and, in the case of cell-based assays, the environment in which the cells are grown impacts cellular physiology. Factors such as microplate geometry, density, surfaces, and instrumentation all play important roles in the success of the assay.
    Learn how to:
    •Select the correct microplate and its role in the success of the assay
    •Choose the correct tip for your liquid handling needs
    •Determine the correct instrumentation and settings to run your assay
  • A Beginner’s Guide to Scaling-Up Cells Recorded: Aug 26 2014 58 mins
    Dr. Katherine Strathearn
    In the past several decades, the usage of mammalian cell culture processes have allowed for better understanding of basic research and manufacturing of higher quality products compared to previous methods. Although much progress has been developed throughout the years, limitations and challenges during optimization of such processes in scale-up of mammalian cell cultures may be encountered.

    This webinar will provide a simple guide and review of novel cell culture vessels and surface technologies that have enabled researchers to improve suspension and adherent mammalian cell culture scale-up. Additionally, this webinar will cover certain parameters to consider when scaling-up cells. Selecting the correct vessel and cell culture conditions will increase throughput without increasing laboratory space, incubator space, or time.
  • Genetic Alteration Cell Panels: Tools for High Throughput In Vitro Screening Recorded: Aug 6 2014 52 mins
    Fang Tian, Ph.D. & David Randle, PhD
    Extensive genomic sequencing efforts in recent years have provided detailed profiles of the somatic gene mutations that occur in a wide range of human cancers. In order to facilitate basic and translational cancer research, ATCC has designed and validated a number of genetic alteration cell panels targeting the key molecular pathways identified in these studies. To demonstrate suitability of the panels for high throughput screening, the EGFR panel was selected for evaluation using Corning® Epic® Technology, a label-free platform that uses optical biosensors for high sensitivity biochemical and cell-based assays.
    Label-free dynamic mass redistribution (DMR) responses in whole cells provide phenotypic activity profiles which are readily amenable to evaluation of compound activity and pharmacology. DMR responses obtained using the EGFR cell panel showed that Epic Technology can be utilized to evaluate receptor responsiveness to ligands and successfully predict drug response. Furthermore, label-free phenotypic responses can provide profiles of cellular signaling pathways downstream of receptor activation that may identify alternative targets for drug screening in the cell panel. In summary, combining Epic Technology and the EGFR genetic alternation panel offers convenient tools to screen for ligands or biologics that directly target or affect EGFR receptor biology.
  • Partnering With Corning® Gentest℠ Contract Research For In Vitro ADME Testing Recorded: Jul 22 2014 60 mins
    David M. Stresser, Ph.D.
    In this webinar, you will learn why partnering with Corning® GentestSM Contract Research will enable your company to reach goals faster. You will also learn about our latest service offerings, including new CYP induction and SLC transporter assay services - all designed to align with regulatory agency guidance documents. These services continue to strengthen our in vitro drug-drug interaction testing portfolio with a deep focus on enzyme inhibition, induction, and transport.
  • Applications of Corning® FluoroBlok™ Permeable Supports Recorded: Jun 25 2014 57 mins
    Jeffrey Partridge
    In vitro cell migration and invasion assays are frequently used as model systems for studying the directed movement of cells towards a chemoattractant stimulus, or to determine how a particular drug, growth factor or extra cellular matrix coating affects that movement. The classic method used to analyze this movement, the Boyden chamber, can be time-consuming, labor-intensive, and subjective.
    An improved version of this technology was developed, Corning FluoroBlok. As cells migrate or invade through a fluorescence blocking membrane, they are detected using a bottom-reading microplate reader or inverted fluorescence microscope. Cells remaining in the upper chamber of the insert are shielded from detection, allowing for quantitation of cell numbers in this homogeneous assay system.
    Recommended uses of the FluoroBlok system as well as recent improvements will be reviewed in this seminar.
  • Corning® Matrigel® Matrix: Material Properties, Applications and Proper Usage Recorded: May 22 2014 61 mins
    Shabana Islam, PhD
    The extracellular matrix (ECM) is a complex material that serves to stabilize tissues, promote cell attachment, and modulate cell functionality by specifically interacting with cell surface receptors. This material has been shown to play structural, biochemical and mechanical roles in the normal growth and differentiation of various cell types. Corning Matrigel Matrix, an ECM-based material isolated from EHS mouse tumors, is a widely used solubilized basement membrane preparation. Based on its physiological composition and functionality, Matrigel Matrix effectively models the physical interplay between diverse cell types and the ECM microenvironment in vivo.
  • Animal-free, Synthetic Surfaces for Cell Types Relevant in Clinical Research Recorded: Apr 24 2014 42 mins
    Deepa Saxena
    Expansion of stem cells and some primary cells requires either animal-origin components in culture media or coating of the culture vessels with human or animal-derived extracellular matrix (ECM) protein. Growing concerns about introducing human and animal-derived pathogens into the culture necessitate the need for animal- free (xeno-free and human-origin components-free) culture environment. Herein, we present defined and synthetic surfaces for cell culture. Corning® PureCoat™ ECM Mimetic cultureware collagen I peptide and fibronectin peptide support culture of cell types requiring collagen I or fibronectin protein -coated surfaces. Corning Synthemax® surface consists of a vitronectin peptide and supports undifferentiated expansion of human pluripotent stem cells (hPSC) and neural progenitor cells (NPCs). ECM Mimetic and Synthemax cultureware are pre-coated, synthetic, animal-free, and room temperature stable. Synthemax-SC is available for self-coating.

    We demonstrate expansion and functionality of several clinically relevant cell types including hPSCs, mesenchymal stem cells (MSCs), human keratinocytes (HKN), endothelial colony forming cells (ECFCs), NPCs and cell lines for biomanufacturing (CHO and Vero) on these surfaces. Corning Synthemax and ECM Mimetic cultureware are versatile surfaces compatible with multiple media for culture of various cell types providing a ready to use alternative to ECM protein coating where animal-free and defined conditions are desirable.
  • Corning TransportoCells™, A Novel “Thaw and Go” Cell-based Transporter Model Recorded: Mar 31 2014 54 mins
    Na Li
    SLC transporter-mediated drug–drug interactions (DDI) can significantly impact the pharmacokinetics and safety profiles of drugs. The regulatory agencies (FDA/EMA) recent guidance documents recommend testing six SLC transporters for potential DDI: OATP1B1, OATP1B3, OAT1, OAT3, OCT1 and OCT2. The 2013 drug transporter white paper published by the International Transporter Consortium (ITC) identified additional drug transporters relevant to drug development, including the Multidrug and Toxin Extrusion SLC transporters: MATE1 and MATE2-K. The webinar will introduce a novel cell-based SLC transporter model system - the recently launched “Corning™ TransportoCells™” - for studying regulatory agency recommended SLC transporters. The new system provides a convenient “thaw and go”, high performing mammalian cell model which supports regulatory agency recommendations for evaluating transporter mediated drug-drug interactions in vitro. In this webinar, we will provide an overview of the product validation and applications for the TransportoCells™ transporter model system. Validation data will also be presented for the newly available MATE1 and MATE2-K Corning™ TransportoCells™.
  • Materials and Systems for Optimizing 3D Cell Culture Environments Recorded: Feb 18 2014 64 mins
    Marshall Kosovsky, Ph.D.
    Three-dimensional (3D) cell culture environments provide structural and biochemical cues for cellular differentiation and functionality. For specialized cell types such as primary cells, a two-dimensional growth substrate may not be sufficient to support complex cellular behaviors such as cell polarity, morphology, signal transduction, and tissue-specific gene expression. This webinar will highlight applications that rely on 3D materials and systems, including Corning ® Matrigel® Matrix (reconstituted basement membrane), Collagen Type I, Corning PuraMatrix™ Peptide Hydrogel, and permeable supports (cell culture inserts). To demonstrate the effectiveness of these environments, the biological and functional properties of a variety of cell types will be discussed.
  • Development of Hydrogel-Based 3D Cancer Stem Cell & Tumorsphere Models for HTS Recorded: Dec 3 2013 48 mins
    Lesley A. Mathews Griner and Madhu Lal-Nag
    Cancer stem cells (CSCs), commonly referred to as tumor initiating cells (TICs), are thought to be the origin of replicating malignant cells that remain after the primary tumor is removed or eradicated. While the contribution of TICs to cancers of hematopoietic origin is well established, there is a growing body of evidence that supports the presence of TICs within solid tumors. This heterogeneity contributes to the intrinsic resistance of solid tumors to chemotherapeutics and eventually leads to therapeutic failure and patient death. Historically, screening for oncology directed compounds has been performed in 2-dimensional monolayer cultures which fail to replicate the complex architecture and microenvironment of tumors in vivo. To address this need using prototype manufactured 384-well round bottom clear black plates coated with hydrogel (commonly referred to as ultra-low attachment or ULA plates) we have developed a method to generate single cell type spheroids to accommodate their use in high throughput screening. These cultures were systematically compared to spheres grown in conventional plates and comparative imaging analyses were carried out to assess sphere formation. In addition, using the same plates, we have developed multicellular tumor spheroids (MCTS) composed of various cell types cultured in the same well. Differences in the cellular compositions of these spheroids in response to drugs can be quantified using high content imagers such as the WiScan from Idea-Bio and the High Throughput Flow Cytometer from IntelliCyt. These heterotypic, differentially labeled spheroids are a valuable asset in the generation of cell-based HTS assays capable of identifying molecules that selectively kill TICs and the cells comprising their microenvironment.
  • Corning® TransportoCells™: Overview of a Novel SLC Transporter Model Recorded: Nov 14 2013 49 mins
    Na Li
    During the past decade, the significant role of transporters in drug disposition and safety has been strengthened due to the increasing evidence of transporter mediated drug-drug interaction (DDI). Regulatory agencies recommend evaluating specific drug transporters of emerging importance in drug development. Appropriate in vitro characterization of drug interactions with these transporters facilitates decision-making and development of appropriate clinical plans in drug development. Corning Life Sciences have recently developed a novel SLC transporter model to help the pharmaceutical industry address regulatory guidance in a fast and easy manner. In this webinar, we will provide an overview of the product validation and applications for the recently launched TransportoCells™ cryopreserved SLC transporter model.
  • Overview of In Vitro ABC Transporter Models and Applications Recorded: Oct 29 2013 64 mins
    Na Li
    During the past decade, increasing clinical evidence of transporter mediated drug-drug interaction (DDI) has highlighted the significant role transporters play in drug disposition and safety. Regulatory authorities recommend evaluating specific drug transporters of emerging importance during drug development, including SLC and ABC transporters. ABC transporters are more challenging to study because they are usually expressed on the apical side of cell membrane (i.e., ATP and substrate binding sites facing inside of the cell), which can limit the direct access of compounds to the transporters in the absence of a relevant uptake transport mechanism. It is critical to utilize an appropriate in vitro system to evaluate drug interactions with these transporters in order to gain better insight into the mechanisms of transporter mediated drug disposition and elimination.

    Corning Life Sciences offers a broad spectrum of in vitro models to support drug transporter studies. This webinar will provide an overview of in vitro ABC transporter models, as well as the pros and cons of each model in deciphering drug ADME features.
  • Cell Culture Contamination Part 3 - Strategies for Reducing Contamination Recorded: Sep 24 2013 56 mins
    Hilary Sherman
    In the third part of our three lecture series on cell culture contamination, we will focus on everyday management of cell culture contamination. We will discuss how to reduce cell culture accidents by using good aseptic technique, the importance of freeze stocks, and how to appropriately monitor for contamination. We will also learn how to track down the source of contamination to prevent future accidents.
Training for Life Science Researchers
The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: 3D Cell Culture Without the Fancy Glasses
  • Live at: Jun 23 2011 6:20 pm
  • Presented by: Mary Strother, Ph.D.
  • From:
Your email has been sent.
or close
You must be logged in to email this